We are international

Understanding Pomalyst®
(pomalidomide) capsules

The U.S. Food and Drug Administration (FDA) approved Pomalyst® (pomalidomide) on February 8, 2013, to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

The National Comprehensive Cancer Network (NCNN) has included pomalidomide plus dexamethasone as a salvage therapy option in patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy. For steroid-intolerant individuals, the NCNN Multiple Myeloma Panel suggests considering pomalidomide monotherapy.


1 Comment

In Italia quando sarà introdotto? non ho pototo avere notizie in merito, mia moglie dal 2005 è affetta da MM residtente. Grazie

Leave a comment

 related articles